<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HA3D933655FC04C7883A4760BCB2C1830" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 4275 IH: Empowering Pharmacists in the Fight Against Opioid Abuse Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-11-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4275</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20171107">November 7, 2017</action-date><action-desc><sponsor name-id="D000623">Mr. DeSaulnier</sponsor> (for himself and <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To provide for the development and dissemination of programs and materials for training
			 pharmacists, health care providers, and patients on indicators that a
			 prescription is fraudulent, forged, or otherwise indicative of abuse or
			 diversion, and for other purposes.</official-title></form>
	<legis-body id="H818BA33811EF42DFA8B72DDB0183B210" style="OLC">
 <section id="H3A023E6F7792437BAB5F210F573874BB" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Empowering Pharmacists in the Fight Against Opioid Abuse Act</short-title></quote>.</text> </section><section id="H9C1AF5D0555B496E9DF44141C2F595AE"><enum>2.</enum><header>Programs and materials for training on certain circumstances under which a pharmacist may decline to fill a prescription</header> <subsection id="H23652BEA55E8431BBE1C8D108A9A5093"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration, in consultation with the Secretary of Health and Human Services, the Commissioner of Food and Drugs, the Director of the Centers for Disease Control and Prevention, and the Assistant Secretary for Mental Health and Substance Use, shall develop and disseminate programs and materials for training pharmacists, health care providers, and patients on—</text>
 <paragraph id="HCB53EEAA89C44B02BD5AB5622EAE9E3B"><enum>(1)</enum><text display-inline="yes-display-inline">circumstances under which a pharmacist may, consistent with section 201 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>) and regulations thereunder, including section 1306.04 of title 21, Code of Federal Regulations, decline to fill a prescription for a controlled substance because the pharmacist suspects the prescription is fraudulent, forged, or otherwise indicative of abuse or diversion; and</text>
 </paragraph><paragraph id="H71AA7C57A40C483F884FEA30E33F2CC7"><enum>(2)</enum><text>any Federal requirements pertaining to declining to fill a prescription under such cir­cum­stances.</text> </paragraph></subsection><subsection id="H8F3A35FFB4C54790B130F111F4D61DF0"><enum>(b)</enum><header>Materials included</header><text display-inline="yes-display-inline">In developing materials under subsection (a), the Administrator of the Drug Enforcement Administration shall include information educating—</text>
 <paragraph id="H1BED4691E8B5430BB60A814CCAF85277"><enum>(1)</enum><text>pharmacists on how to decline to fill a prescription and actions to take after declining to fill a prescription; and</text>
 </paragraph><paragraph id="HD79A626C23B147BB9D224E1EC108E5D7"><enum>(2)</enum><text>other health care practitioners and the public on a pharmacist’s responsibility to decline to fill prescriptions in certain circumstances.</text>
 </paragraph></subsection><subsection id="H9F4BABBF878D406BB85BDD5230FA5099"><enum>(c)</enum><header>Stakeholder input</header><text display-inline="yes-display-inline">In developing the programs and materials required under subsection (a), the Administrator of the Drug Enforcement Administration shall seek input from relevant national, State, and local associations, boards of pharmacy, medical societies, licensing boards, health care practitioners, and patients.</text>
			</subsection></section></legis-body></bill>


